Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Liabilities and Shareholders Equity: 2023-2024

Historic Liabilities and Shareholders Equity for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to $370.0 million.

  • Zenas BioPharma's Liabilities and Shareholders Equity fell 20.18% to $322.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year change of. This contributed to the annual value of $370.0 million for FY2024, which is 442.63% up from last year.
  • According to the latest figures from FY2024, Zenas BioPharma's Liabilities and Shareholders Equity is $370.0 million, which was up 442.63% from $68.2 million recorded in FY2023.
  • In the past 5 years, Zenas BioPharma's Liabilities and Shareholders Equity registered a high of $370.0 million during FY2024, and its lowest value of $68.2 million during FY2023.
  • Moreover, its 2-year median value for Liabilities and Shareholders Equity was $219.1 million (2023), whereas its average is $219.1 million.
  • Data for Zenas BioPharma's Liabilities and Shareholders Equity shows a peak YoY surged of 442.63% (in 2024) over the last 5 years.
  • Over the past 2 years, Zenas BioPharma's Liabilities and Shareholders Equity (Yearly) stood at $68.2 million in 2023, then spiked by 442.63% to $370.0 million in 2024.